Publications by authors named "James Limberis"

Claim this Profile
F
Functional α6β4 acetylcholine receptor expression enables pharmacological testing of nicotinic agonists with analgesic properties.
Daniel Knowland, Shenyan Gu, William A Eckert, G Brent Dawe, Jose A Matta, James Limberis

J Clin Invest· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Azetidine-based selective glycine transporter-1 (GlyT1) inhibitors with memory enhancing properties.
Andrew R Hudson, Vincent J Santora, Robert E Petroski, Theresa A Almos, Gary Anderson, James Limberis

Bioorg Med Chem Lett· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties.
Vincent J Santora, Theresa A Almos, Richard Barido, Jillian Basinger, Chris L Bellows, James Limberis

J Med Chem· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eleclazine exhibits enhanced selectivity for long QT syndrome type 3-associated late Na current.
Nesrine El-Bizri, Cheng Xie, Lynda Liu, James Limberis, Michael Krause

Heart Rhythm· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Selective Phosphodiesterase 1 Inhibitors with Memory Enhancing Properties.
Brian Dyck, Bryan Branstetter, Tawfik Gharbaoui, Andrew R Hudson, J Guy Breitenbucher, James Limberis

J Med Chem· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of A-935142, a hERG enhancer, in the presence and absence of standard hERG blockers.
Xiaoqin Liu, James T Limberis, Zhi Su, Kathryn Houseman, Gilbert J Diaz

Life Sci· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Ventricular rate adaptation: a novel, rapid, cellular-based in-vitro assay to identify proarrhythmic and torsadogenic compounds.
Jonathon R Green, Gilbert J Diaz, James T Limberis, Kathryn A Houseman, Zhi Su

J Pharmacol Toxicol Methods· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Negative inotropic effect of a CB2 agonist A-955840 in isolated rabbit ventricular myocytes is independent of CB1 and CB2 receptors.
Zhi Su, Lee Preusser, Gilbert Diaz, Jonathon Green, Xiaoqin Liu, James T Limberis

Curr Drug Saf· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative analysis of inactivated-state block of N-type (Ca(v)2.2) calcium channels.
Timothy A Vortherms, Andrew M Swensen, Wende Niforatos, James T Limberis, Torben R Neelands

Inflamm Res· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel secretagogue increases cardiac contractility by enhancement of L-type Ca2+ current.
Zhi Su, Deborah L Widomski, Xiaoqin Liu, James T Limberis, Jonathon Green

Biochem Pharmacol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Electrophysiologic characterization of a novel hERG channel activator.
Zhi Su, James Limberis, Andrew Souers, Philip Kym, Ann Mikhail

Biochem Pharmacol· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional consequences of methionine oxidation of hERG potassium channels.
Zhi Su, James Limberis, Ruth L Martin, Rong Xu, Katrin Kolbe

Biochem Pharmacol· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of plasma proteins on delayed repolarization in vitro with cisapride, risperidone, and D, L-sotalol.
James T Limberis, Jeff S McDermott, Heinz J Salmen, Zhi Su, Ann Mikhail

J Pharmacol Toxicol Methods· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hydroxypropyl beta-cyclodextrins: a misleading vehicle for the in vitro hERG current assay.
Ann Mikhail, Cristina Fischer, Ameesha Patel, Michelle A Long, James T Limberis

J Cardiovasc Pharmacol· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of diamino chromone-2-carboxamides as MCHr1 antagonists with minimal hERG channel activity.
Andrew S Judd, Andrew J Souers, Dariusz Wodka, Gang Zhao, Mathew M Mulhern, James T Limberis

Bioorg Med Chem Lett· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Altering extracellular potassium concentration does not modulate drug block of human ether-a-go-go-related gene (hERG) channels.
James T Limberis, Zhi Su, Bryan F Cox, Gary A Gintant, Ruth L Martin

Clin Exp Pharmacol Physiol· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of chromone-2-carboxamide melanin concentrating hormone receptor 1 antagonists: assessment of potency, efficacy, and cardiovascular safety.
John K Lynch, Jennifer C Freeman, Andrew S Judd, Rajesh Iyengar, Mathew Mulhern, James T Limberis

J Med Chem· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro preclinical cardiac assessment of tolterodine and terodiline: multiple factors predict the clinical experience.
Ruth L Martin, Zhi Su, James T Limberis, Jason D Palmatier, Marlon D Cowart

J Cardiovasc Pharmacol· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Parallel synthesis of a biased library of thiazolidinones as novel sodium channel antagonists.
Qun Sun, Laykea Tafesse, James T Limberis, Khondekar Islam, Donald J Kyle

Comb Chem High Throughput Screen· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties.
Kenneth J Valenzano, Elfrida R Grant, Gang Wu, Mohamed Hachicha, Lori Schmid, James Limberis

J Pharmacol Exp Ther· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis